Maze Therapeutics, INC 8-K filings

Maze Therapeutics announced its second quarter 2026 financial results, highlighting progress in its MZE829 and MZE782 clinical trials and a strong cash position extending runway into 2029.

Maze Therapeutics stockholders elected two Class I directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

Maze Therapeutics announced the resignation of Senior Vice President of Finance, Amy Bachrodt, effective June 1, 2026.

Maze Therapeutics announced positive topline data from its Phase 2 HORIZON trial for MZE829 in AMKD, alongside strong financial results and an extended cash runway into 2029.

Maze Therapeutics has priced a $150 million public offering of common stock and pre-funded warrants to extend its cash runway into 2029.

Maze Therapeutics announced positive topline Phase 2 data for MZE829 in APOL1-mediated kidney disease, alongside its Q4 and full-year 2025 financial results and a new board appointment.

Maze Therapeutics, Inc. secured a new senior secured term loan facility of up to $200 million from Hercules Capital, Inc., replacing its previous agreement with Banc of California.

Maze Therapeutics reported its third quarter 2025 financial results, highlighting positive Phase 1 MZE782 data and ongoing enrollment for MZE829, backed by a strong cash position.

Maze Therapeutics, Inc. announced the appointment of Hervé Hoppenot, a seasoned pharmaceutical executive, as its new Chairman of the Board and Class II director, effective October 6, 2025.

Maze Therapeutics raises $150M; MZE782 Phase 1 positive.

Maze Therapeutics, Inc. announced the appointment of Misbah Tahir as its new Chief Financial Officer, effective September 2, 2025.

Maze Therapeutics reports Q2 2025 financial results, highlighting progress in its clinical programs and a robust cash position.

Maze Therapeutics announced its Q1 2025 financial results, highlighting a strong cash position and reiterating key milestones for its MZE829 and MZE782 clinical programs.

Maze Therapeutics announces fourth quarter and full-year 2024 financial results, highlighting clinical trial advancements and a successful IPO.